StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Kisqali (ribociclib by Year

Kisqali (ribociclib — HR+/HER2- eBC & mBC breast cancer) ($M)

QuarterlyAnnual

Novartis Kisqali (ribociclib: $4,783M in FY2025, up 57.7% from a year earlier. That is the highest of the 9 years on record here.

Latest, FY2025
4,783
Period ended Dec 31, 2025
Change on a year earlier
+57.7%
3,033 in FY2024
History
9 years
Since FY2017
Sources
7
Documents cited below

Where the FY2025 figure comes from

“|| Kisqali | 4 783 | 3 033 | 58 | 57”

Source: Novartis Form 6-K (0001114448-26-000007) ↗

Reported in Form 6-K & Form 20-F.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedKisqali (ribociclib — HR+/HER2- eBC & mBC breast cancer) ($M)Year on yearSource
FY2025Dec 31, 20254,783+57.7%Novartis Form 6-K (0001114448-26-000007) ↗
FY2024Dec 31, 20243,033+45.8%Novartis Form 6-K (0001114448-26-000007) ↗
FY2023Dec 31, 20232,080+69.0%Novartis Form 6-K (0001370368-25-000007) ↗
FY2022Dec 31, 20221,231+31.4%Novartis Form 6-K (0001370368-24-000007) ↗
FY2021Dec 31, 2021937+36.4%Novartis Form 6-K (0001370368-23-000008) ↗
FY2020Dec 31, 2020687+43.1%Novartis Form 6-K (0001370368-21-000008) ↗
FY2019Dec 31, 2019480+104.3%Novartis Form 6-K (0001370368-21-000008) ↗
FY2018Dec 31, 2018235+209.2%Novartis Form 6-K (0001370368-20-000007) ↗
FY2017Dec 31, 201776–Novartis Form 6-K (0001370368-19-000006) ↗

Breakdown

What makes up kisqali (ribociclib

Cite this data

StockData. (2026). Novartis Kisqali (ribociclib ($M), annual FY2017–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-kisqali

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.